Suven Life Sciences Update by Epic Research

Suven Life Sciences’ drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators which resulted in the grant of one product patent from USA, corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this patent is valid through 2030.



For Real Time News & Trading Trends Keep Liking Epic Research Private Limited



Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+

Posted in: Indian Market Tips